The iPhone 11 2020 best-selling world mobile in the first half of the year and purchases of the Apple model triple those of Samsung - Apple is in good health despite the pandemic. Moreover, the company believes that the coronavirus will not pass the bill and the market data give the reason.

The iPhone 11 was the best-selling mobile phone in the world in the first half of the year, with 37.7 million units distributed, according to data from analysis firm Omdia. Thus, Apple has tripled the numbers of Samsung's Galaxy A51, the second most demanded smartphone. In its case, with 11.4 million buyers.

"One of the reasons for the success of the iPhone 11 is a lower starting price. The iPhone 11 was released 50 dollars (41,7 euros) cheaper than the previous iPhone XR and with significant improvements in its hardware, such as the dual camera. The iPhone XR did not include such improvements, " explains the consultant.

But not only is it that the firm has placed number 1 in the ranking of the best sellers, but 5 of its models are among the 10 most popular.

In this way, the ranking is like this: iPhone 11 (37.7 million), Galaxy A51 (11.4 million), Redmi Note 8 (11 million), Redmi Note 8 Pro (10.2 million), iphones (8.7 million), iPhone, XR (8 million), iPhone 11 Pro Max (7.7 million), Redmi 8A (7.3 million), the Redmi 8 (6.8 million) and iPhone 11 Pro (6.8 million).

iPhone 11 2020 best-selling world mobile

As seen in the omdia rating, consumers are still betting on the iPhone, which has recorded good sales figures, despite the coronavirus.

There is No doubt that Apple is a solid alternative, even if its terminals are more expensive than those of other manufacturers. What's more, the best-selling mobile, the iPhone 11 is the only high-end that gets into that list.

But Tim Cook's firm is not only doing well in terms of its hardware, but its good work has been reflected in the markets. Apple can boast of having exceeded $ 2.000 million (1.600 million euros) of market capitalization, being the first American company to do so.

One of the strengths of the technology is the loyalty of its users, something that undoubtedly supports the brand. In fact, consumers are still getting on with the iPhone 11, betting on this device, even though the next launch of the brand is expected shortly, in the second half of 2020. This is the iPhone 12, which will already include 5G.

Although not only Cupertino (California, USA) can rejoice in these good results. The Chinese company Xiaomi has improved its presence in the market compared to the first 6 months of last year. Thus, 2 of their devices were among the best-selling, while, currently, there are 4 that are listed in Omdia.

In addition to their phones gaining ground, the firm is positioned as one of the most sold, being the Redmi Note 8 Pro the third most successful model, only behind the iPhone 11 and the Galaxy A51.

Precisely, the boom of this brand resides in Spain and Europe. At the national level, Xiaomi is the largest smartphone distributor, followed by competitors such as Samsung and Huawei, according to data from Canalys. 6 months ago the company achieved the first position, which it has maintained to this day.

Its market share from April to June in Spain was 36.8%. This means that, by sales to distributors, Xiaomi has placed more than 1 out of 3 mobile phones in our country. Meanwhile, in Europe, it still occupies the fourth position in terms of market volume, with 12.4% of the units placed.

End of iPhone 11 2020 best-selling world mobile


More on

Who puts a stop to the use of experimental vaccines that have not completed their testing phase

The World Health Organization (who) does not want to take false steps. Abusing shortcuts in the event of a health emergency and approving the use of a Covid-19 vaccine for emergency use without the completion of clinical trials could distort the results and fail to show its true efficacy and safety.

This was explained this Tuesday the chief scientist of the agency, Soumya Swaminathan, who warned that the approval of a vaccine should be made on the basis of data obtained in Phase III of the tests to avoid risks.

Among them, he stressed the possibility that the effectiveness would be too low, so "it would not do its job to end this pandemic". If this is the case, randomised clinical trials may have problems continuing.

The WHO and the regulatory agencies agreed that the level of effectiveness should be at least 50% "and preferably higher", clarified the scientist. "Ideally, we don't want a vaccine less than 30% effective that gets approved," he added.
External pressures

The race for the Covid-19 vaccine is the final stretch and pharmacists are in a hurry to become the winner. "The most important thing is that decisions are made based on what the science says and have a group of scientists who are not influenced by any interest, who analyze the data and recommend whether a vaccine should be approved," said Swaminathan.

Phase II of the research involves supplying the vaccine to hundreds of people, while in the last and third stages the tests are carried out in a massive way, in more than 30,000 volunteers(the pharmaceutical company Johnson & Johnson has 60,000 people).

The concern of the scientific community arises in the wake of the approval of the Russian vaccine in mid-August, when the Kremlin launched into mass vaccination without having completed clinical trials. Something similar happened in China days later and announced the approval of its first patent, developed by the laboratory Cansino Biologics.

"We need the efficacy and safety results of these studies because if we start vaccinating millions of people very quickly we can overlook some adverse effects," Who Emergency Director Mike Ryan said at a press conference.

On the other hand, it should also be borne in mind that 2020 is an election year. Donald Trump hopes to be re-elected to remain at the head of the US government and arrive on November 3 with a vaccine could expand his possibilities.

In May, the Trump administration created Operation Warp Speed, which sought to accelerate the production and distribution of the vaccine. The goal was to have 100 million doses available by November, 200 million by December and 300 million by January.

However, the food and Drug Administration (FDA) published a vaccine guide that stated that any antiviral must prove to be at least 50% more effective than a placebo to obtain approval, so simply showing immunity data would not be enough.

But the tycoon is in a hurry. The call to the polls is approaching, which raises the possibility of circumventing normal regulatory standards and speeding up the approval of the vaccine being developed by the University of Oxford together with the British laboratory Astrazeneca.

The trap is to issue an "emergency use permit", based on the results of a relatively small UK study. And this shortcut is what the who criticized this Tuesday.

"Scientists around the world are asking regulatory agencies and companies to approve a vaccine based on data from Phase 3 clinical trials," concluded Swaminathan.

You may also find interesting: